Design, manufacture and initial tests of a drug-eluting coronary stent

A drug-eluting coronary stent is being developed at the National Institute of Cardiology of Mexico for the treatment of ischemic heart disease. To establish the best animal model for the tests, to show the advances in the drug-eluting stent prototype, to assess two drugs' antiproliferative acti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gaceta médica de México 2020, Vol.156 (4), p.279-285
Hauptverfasser: Abundes-Velasco, Arturo, Padilla-Ibarra, Jorge, Jiménez-Rodríguez, Gian M, Farjat-Pasos, Julio I, Arias-Sánchez, Eduardo A, Santos, Félix Damas-de Los, Martínez-Ríos, Marco A, Molina-Méndez, Francisco J, Sánchez-Pérez, Tomás E, Arai-Ito, Marco M, González, Sebastián Aceves-Díaz, Rodríguez-Parra, David A, Aranda-Fraustro, Alberto, Masso-Rojas, Felipe A, Galaz-Méndez, Ramsés, Peña-Duque, Marco A
Format: Artikel
Sprache:eng ; spa
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A drug-eluting coronary stent is being developed at the National Institute of Cardiology of Mexico for the treatment of ischemic heart disease. To establish the best animal model for the tests, to show the advances in the drug-eluting stent prototype, to assess two drugs' antiproliferative activity and histological results. Smooth muscle cell culture tests were performed in order to assess sirolimus and paclitaxel antiproliferative properties. The drugs were encapsulated inside the polymeric matrix of the stents. Rabbits and pigs were used as animal models. Sirolimus and paclitaxel showed an inhibitory effect, which was higher for the latter. Infrared spectroscopy and light and optical microscopy showed that the drug/polymer layer properly adhered to the stent. At a four-week follow-up, both animal models showed satisfactory clinical evolution and adequate histological response, although the porcine model was shown to be more suitable for future protocols. Preliminary tests of the drug-eluting stent provided bases for the development of a study protocol with an adequate number of pigs and with clinical angiographic and histopathological three-month follow-up.
ISSN:0016-3813
DOI:10.24875/GMM.20005675